Comcast Corporation (NASDAQ:CMCSA) said shareholders voted by an overwhelming margin to approve its $45 billion acquisition of Time Warner Cable (TWC). Shares of both companies rose slightly Wednesday. Comcast Corporation (NASDAQ:CMCSA) said 99% of shareholders voted approval of a plan to issue 2.875 shares of Comcast Class A common stock for every one share of Time Warner Cable common stock for the proposed merger of the companies. The deal is still is subject to various regulatory approvals and faces additional FCC scrutiny. It also requires approval by Time Warner Cable shareholders, who are expected to vote on the merger Thursday. If approved, the merger is expected to close in early 2015.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), biopharmaceutical company developing and commercializing treatments for infectious diseases, said Wednesday that it will provide updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naive genotype 1 chronic hepatitis C virus (HCV) infection.
The results are part of four abstracts that have been accepted for presentation at The Liver Meeting 2014, the 65th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), in Boston, November 7-11. Three additional posters will be presented detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide that continues to advance through its Phase 1 clinical development program.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, said Thursday that after the independent Data and Safety Monitoring Board (DSMB) for Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Phase 3 SEAMLESS study in acute myeloid leukemia (AML), has recommended that the study should continue as planned without any modifications. Following the fourth planned safety review, which looked at available data from 317 randomized patients with at least 60 days of follow-up, the DSMB said no safety or efficacy concerns were identified
SEAMLESS is a Phase 3, randomized, registration-directed study of oral sapacitabine capsules in elderly (70 years or older) patients with AML who are unfit for or have refused intensive chemotherapy. The primary endpoint is overall survival. SEAMLESS is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The DSMB will perform an interim analysis for futility once half of the required events have been observed.